Daily Brief Health Care: New Horizon Health , Shouhui Tech, Johnson & Johnson, SIGA Technologies and more

• New Horizon Health announced a positive profit alert yesterday after market close and held a conference call.
• We participated in the call and spoke with the management to understand the recent developments.
• The company upgraded ’23 revenue guidance and provided revenue guidance for ’24.

• The essence of Shouhui’s business model is to “sell insurance” rather than provide services with technological attributes. So, Shouhui has relatively single business composition and lacks diversified sources of revenue.
• The trend of “disintermediation” is becoming increasingly evident, which may lead to customers deciding to purchase insurance directly from insurance companies not from Shouhui, resulting declining demand for Shouhui’s services/products.
• The business nature of insurance is incompatible with the Internet’s pursuit of rapid expansion. Cooling “Internet +insurance” investment in recent years proves the decline of market’s enthusiasm for this business.

• Like everyone else on the planet, Calcbench has been relieved to see the covid-19 pandemic recede into the background of daily life.
• Now, however, Johnson & Johnson ’s latest earnings report gives us a glimpse of what that fade means for corporate earnings.
• J&J ($JNJ) filed its earnings report on Tuesday morning .

SIGA Technologies has appointed Dr Diem Nguyen as its new chief executive officer (CEO), effective 27 January 2024. She will be spearheading the company efforts to expand its commercial operations, following the retirement of incumbent CEO, Dr Phil Gomez (who had announced plans to retire in January 2023). Dr Nguyen has over 25 years of experience in the pharmaceutical industry and joins from Xalud Therapeutics, a clinical-stage biotechnology company, where she was the CEO. Prior to Xalud, she served as executive vice president of PPD Inc, a global contract research organization (CRO) and had previously been associated with Pfizer across various commercial roles. We expect SIGA to benefit from her broad industry exposure and commercial know-how in scaling the international footprint of SIGA’s antiviral treatment, TPOXX, the only approved antiviral treatment for smallpox globally.